Flu jab for additional groups The flu jab is offered free of charge every year to people aged 60 years and older, and to people who are at higher risk of becoming seriously ill from the flu virus due to medical reasons
Launch of the European project RISK-HUNT3R The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.
Last winter’s flu epidemic was short and mild. And then COVID-19 arrived. The flu epidemic in the winter of 2019/2020 was mild and lasted only 5 weeks.
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Mild 2018-2019 influenza epidemic The annual influenza epidemic in the winter of 2018-2019 was less severe than the year before. Approximately 400,000 people have had the flu.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.